Contains the active ingredient Linagliptin, which is a type of medicine called a dipeptidyl peptidase-4 (DPP-4) inhibitor.
Linagliptin works by increasing the amount of two incretin hormones found in the body, called glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). These hormones are normally produced naturally by the body in response to food intake. Their function is to help control blood sugar (glucose) levels.
GLP-1 and GIP have two main actions that help to control blood glucose.
Firstly, they stimulate the pancreas to produce insulin in response to increasing levels of glucose in the blood. (Insulin is the main hormone responsible for controlling sugar levels in the blood. It causes cells in the body to remove sugar from the blood.)
GLP-1 also reduces the production of glucagon. (Glucagon is a hormone that normally increases glucose production by the liver.)
GLP-1 and GIP are normally broken down by an enzyme in the body called dipeptidyl peptidase-4 (DPP-4). Linagliptin works by binding to this enzyme and preventing it from breaking down the GLP-1 and GIP. This increases the levels of these hormones in the body and so increases their effect on controlling blood sugar.
What is it used for?
Type 2 diabetes (non-insulin dependent diabetes).
Trajenta can be used on their own to improve blood sugar control in people whose blood sugar is not controlled by changes to their diet and exercise alone, and who can't take metformin.
Trajenta can also be used for people with type 2 diabetes whose blood sugar is not sufficiently controlled by other antidiabetic medicines. It can be added to treatment with metformin, to treatment with metformin plus a sulphonylurea such as gliclazide or glibenclamide, or to treatment with insulin either with or without metformin.
Size : 30 tablets/box